KRAS and non-small cell lung carcinoma: A phase II clinical trial evaluated the efficacy of adagrasib in patients with KRAS-G12C-mutant NSCLC previously treated with platinum-based chemotherapy and anti-PD-1 or PD-L1 therapy.